Skip to content
Login Register

#CD20

3 public questions tagged with this topic.

Immunological Applications

Rituximab targets which antigen?

MS4A1 gene on chromosome 11q12.2 encodes CD20 differentiation antigen, 33 to 37 kDa tetra-spanning membrane phosphoprotein with both N and C termini intracellular, four transmembrane helices forming tetrameric oligomer functioning as store-operated calcium channel component modulating B cell receptor induced calcium flux via interaction with calcium release-activated calcium modulator ORAI1. Expression tightly regulated during ontogeny: absent on hematopoietic stem cells and early pro-B, appears at late pro-B stage after productive immunoglobulin heavy chain rearrangement, persists through mat

Ref: NCBI Gene MS4A1 CD20 tetra-span; Janeway Immunobiology CD20 calcium channel rituximab ADCC CDC.

View Details
Immunological Applications

Rituximab targets which antigen?

Rituximab first chimeric mouse-human IgG1 kappa mAb targeting CD20 tetra-spanning membrane protein 33-37 kDa encoded MS4A1 11q12 four hydrophobic transmembrane domains intracellular N C termini extracellular small large loops 44 aa large loop epitope. CD20 forms homodimers tetramers lipid rafts regulating calcium flux store-operated entry Orai1 STIM1 and BCR signaling amplifying PLC gamma. Expression pre-B mature B lymphocytes but absent plasma cells HSC no shedding soluble form slow internalization excellent therapeutic target. Binding rituximab large loop crosslinks CD20 redistribution lipid

Ref: FDA Rituxan Rituximab CD20 MOA Label; NEJM Rituximab Lymphoma 1997 Maloney; Janeway CD20 Depletion ADCC CDC Mechanism Chapter 5.

View Details
Basic Applied Biology

Rituximab targets antigen:

Rituximab represents first chimeric anti-cancer monoclonal antibody approved 1997 targeting CD20, a 33 to 37 kDa non-glycosylated tetra-span membrane phosphoprotein encoded by MS4A1 gene on chromosome 11q12 expressed on pre-B through mature B lymphocytes but absent on hematopoietic stem cells, pro-B cells and terminally differentiated plasma cells. Protein architecture comprises four transmembrane domains with short intracellular termini and two extracellular loops accessible for antibody binding. Physiologic function involves regulation of calcium flux through modulating B cell receptor signa

Ref: Maloney et al. Blood 1997 Rituximab ideal target; Reff et al. CD20 biology; PubMed review CD20 therapeutic target.

View Details